BioSpace News Archive

Premia Spine, a medical technology company changing the way debilitating chronic leg and back pain is treated, today announced that a single-center study evaluating its TOPS™ System for lumbar spinal stenosis and degenerative spondylolisthesis has been published in the journal Operative Neurosurgery.

2seventy bio, Inc. (Nasdaq: TSVT) today announced plans to initiate the KarMMa-9 study to evaluate Abecma (idecabtagene vicleucel) in newly diagnosed multiple myeloma patients who have suboptimal response to transplant.

AIM ImmunoTech Inc. announced that Thomas K. Equels, M.S. J.D. Chief Executive Officer of AIM, will present at the virtual H.C. Wainwright 24th Annual Global Investment Conference being held in New York, N.Y., and virtually, September 12-14, 2022.

Sernova Corp., a clinical-stage company and leader in regenerative medicine cell therapeutics, announced the appointment of Daniel Mahony, Ph.D. to its Board of Directors, effective September 30th, 2022.

TRACON Pharmaceuticals, Inc. announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate at the following upcoming investor conferences and provide a company overview.

Strata Oncology, Inc. announced the integration of discrete genomic data from its StrataNGS® next-generation sequencing-based tumor profiling with the University of Wisconsin Carbone Cancer Center and UW Health Epic genomics module.

Polycystic ovarian syndrome or PCOS refers to an endocrine disorder that is commonly found in women of reproductive age.

A biological or medical sensor or biosensor is a medical device formed by incorporation of an electrical transducer with a biological element such as enzyme, mineral, nucleic acid, protein, or antibodies.

According to Nova one advisor, the North America Laboratory Informatics market gathered revenue around USD 6.9 billion by the end of 2030 and is estimated to expand at a modest CAGR of 8.8%during the prediction period 2022 to 2030.

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced that it has completed Good Manufacturing Practice (“GMP”) manufacturing of a scaled-up batch of IMX-110 for clinical trials.